Nov 16 (.) – Moderna Inc said Monday that its experimental vaccine was 94.5% effective in preventing COVID-19, based on interim data from an advanced-phase clinical trial, making it the second-largest company in the United States. States that, in a week, reports results that far exceed expectations.
Here are the reactions to the news.
WALID GELLAD, PROFESSOR OF MEDICINE, UNIVERSITY OF PITTSBURGH, PENNSYLVANIA
“Now we know that the vaccine appears to be highly effective. It also seems like we really need the vaccine right now, because we don’t have a coherent national strategy. And the next two months are looking bleak. So there has to be some willingness to uncertainty and flexibility in times of crisis … FDA can safely schedule this committee soon. “
“If you look at the state of the pandemic right now, and the exponential rise and strain on the healthcare system, and the assumption that that’s going to get worse, the increase in cases in nursing homes, the Thanksgiving, and later the Christmas holidays and other holidays, all of that is an environment that is only going to add fuel to the fire (…) with the speed with which things move and the holidays, actually two or three three weeks, I think it makes a big difference right now. “
ANTHONY FAUCI, INFECTIOUS DISEASE EXPERT FROM THE UNITED STATES
“The vaccine is really the light at the end of the tunnel.”
Fauci urged Americans not to let their guard down over the news, but to keep washing their hands, avoiding crowds, and being vigilant about social distancing.
ZOLTAN KIS, ASSOCIATE RESEARCHER, IMPERIAL COLLEGE LONDON VACCINE MANUFACTURING CENTER OF THE FUTURE
“If COVID-19 mRNA vaccines get regulatory approval, this will be a huge validation of the RNA vaccine production platform technology.”
“Using this technology, vaccine candidates can be produced substantially faster in the future to combat virtually any infectious disease, producing vaccines against both existing and currently unknown future pathogens.
“Candidate vaccines can be produced against virtually any disease, because it is a platform technology, which means that the production process, purification processes, and formulation processes can remain the same, regardless of the vaccine or the candidate vaccine to be produced. “
“This is a huge advantage in terms of the speed with which vaccine candidates can be developed and produced in the future.”
“In the case of conventional vaccine production technologies, each vaccine requires the development of a new production process, while in the case of RNA vaccine production platform technology a process can produce vaccines and potential vaccines against virtually any disease. “
PENNY WARD, VISITING PROFESSOR OF PHARMACEUTICAL MEDICINE AT KING’S COLLEGE IN LONDON
“Given the general similarity of the vaccine target and the immune responses seen in all vaccines, these data generally suggest that vaccination will protect against serious disease and therefore should protect people from the need for hospitalization or from death from COVID.
“We still need to know if there is protection against infection, since it translates into herd protection, while protection against disease has value for an individual, it will not impede the circulation of the virus and the risk of disease in people will not vaccinated, or in people who do not respond adequately to vaccination. “
RICHARD HATCHETT, DIRECTOR GENERAL OF THE COALITION OF INNOVATIONS IN EPIDEMIC PREPAREDNESS (CEPI)
“Moderna’s results are as good as we could hope for and really very encouraging.”
“Moderna has also published information suggesting that the vaccine may protect against more serious diseases (although they do not address the statistical significance of this finding), and the reported side effects appear to be manageable.”
“The fact that the vaccine shows stability when stored in a normal refrigerator for up to 30 days is also great news and will allow the vaccine to be widely distributed.”
ANDREW HILL, VISITING SENIOR RESEARCHER, UNIVERSITY OF LIVERPOOL DEPARTMENT OF PHARMACOLOGY
“This vaccine would be much easier to transport and administer than Pfizer’s. Preliminary evidence also suggests that it can prevent severe COVID-19 disease. However, the Moderna vaccine is more expensive and fewer doses are available next year. “.
“No vaccine company has enough supplies available to protect everyone who needs it. We will need all available vaccines more than 90% effective to meet global demand.”
TRUDIE LANG, DIRECTOR, GLOBAL HEALTH NETWORK, NUFFIELD DEPARTMENT OF MEDICINE, UNIVERSITY OF OXFORD
“It is very good news to see another vaccine with efficacy results similar to those reported last week by Pfizer. This is also an interim analysis, which means that there were enough cases in the vaccinated volunteers to give statistical significance and allow the team lifted the veil to determine who had the active vaccine and who had the placebo. “
“Here they found that out of 95 COVID cases, 90 had received the placebo and five the active vaccine. These first results suggest that there was a representation of different age groups and diverse communities in the protected group. This is really encouraging and further shows that a vaccine for COVID is a real probability and that having more than one supplier should help ensure better and more equitable global availability. “
“This vaccine is also an mRNA vaccine, so many of the same questions remain as we have been discussing with the Pfizer vaccine and will be carefully scrutinized by regulators.”
STEPHEN EVANS, PROFESSOR OF PHARMACOEPIDEMIOLOGY, LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE
“This announcement from Moderna is further encouragement to prove that vaccines are not only acceptable, but are much more effective than we had anticipated. This press release is more specific than others, as it confirms the Numbers for each group, which could be guessed, but getting it confirmed is helpful. “
“The range of minor adverse effects reported is not surprising and is typical of almost any vaccine. These reactions tend to be local to the injection site and are rarely long-lasting or severe.”
“Although they reported the efficacy to be greater than 94%, there is statistical uncertainty about this, but based on these data, the likely efficacy will be better than 85%, which would be more than most scientists would have expected. “.
“This is the first study to report on severe cases and, although uncertainty remains, the finding that there are no severe cases with the vaccine and 11 cases with the placebo is very strong evidence that the vaccine prevents both severe disease such as mild. Compelling evidence regarding deaths is likely only when the vaccine is in use. “
“The trials included a wide range of people with illnesses and minority groups, as well as a considerable number of elderly people. We will need much more data and a full report or publication to see if the benefit is consistent across all groups. especially the elderly, but this is definitely an encouraging development. “
DONALD TRUMP, PRESIDENT OF THE UNITED STATES, ON TWITTER: “Another vaccine has just been announced. This time from Moderna, 95% effective. For those great ‘historians’, please remember that these great discoveries, which will end the China Plague, they all happened under my command! “
JOE BIDEN, PRESIDENT-ELECT OF THE UNITED STATES, ON TWITTER:
“Today’s news of a second vaccine is one more reason for hope.”
“What was true with the first vaccine is still true with the second: We are still months away. Until then, Americans must continue to practice social distancing and wearing face masks to get the virus under control.” (Reporting by Josephine Mason, Francesco Guarascio and Michael Erman, Edited in Spanish by Javier López de Lérida)